AACR 2023 | A Phase Ia/Ib trial of BGB-3245, a novel RAF dimer inhibitor, in solid tumors

There are three classes of BRAF mutations, with class I mutations (V600E) being the most common. Current BRAF inhibitors such as vemurafenib, dabrafenib, and encorafenib are predominantly effective in class I mutations, and can cause paradoxical activation in wild type cells. Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a Phase Ia/Ib trial (NCT04249843) of BGB-3245, novel RAF inhibitor targeting all classes of BRAF mutations, in patients with solid tumors. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.